A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Subscribe To Our Newsletter & Stay Updated
